AG˹ٷ

STOCK TITAN

[6-K] ICL Group Ltd. Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary

Jaguar Health, Inc. (NASDAQ: JAGX) received SEC notice that its Form S-3 shelf registration statement (File No. 333-288202) became effective on June 27, 2025 at 4:00 p.m. ET. The effectiveness allows the company to register and potentially issue securities in the future without additional SEC review, streamlining capital-raising activities. No financial terms, transaction details, or earnings information were disclosed in the notice.

Jaguar Health, Inc. (NASDAQ: JAGX) ha ricevuto comunicazione dalla SEC che la sua dichiarazione di registrazione a scaffale Form S-3 (File n. 333-288202) è diventata efficace il 27 giugno 2025 alle 16:00 ET. Tale efficacia consente all'azienda di registrare e potenzialmente emettere titoli in futuro senza ulteriori revisioni da parte della SEC, semplificando le attività di raccolta di capitale. Nel comunicato non sono stati divulgati termini finanziari, dettagli sulle transazioni o informazioni sugli utili.

Jaguar Health, Inc. (NASDAQ: JAGX) recibió aviso de la SEC de que su declaración de registro en estantería Formulario S-3 (Archivo No. 333-288202) se volvió efectiva el 27 de junio de 2025 a las 4:00 p.m. ET. Esta efectividad permite a la empresa registrar y potencialmente emitir valores en el futuro sin revisión adicional de la SEC, agilizando las actividades de recaudación de capital. No se divulgaron términos financieros, detalles de la transacción ni información sobre ganancias en el aviso.

Jaguar Health, Inc. (NASDAQ: JAGX)� SEC로부� Form S-3 선반 등록 명세�(파일 번호 333-288202)가 2025� 6� 27� 오후 4�(동부 시간 기준)� 효력� 발생했다� 통지� 받았습니�. � 효력 발생으로 회사� 향후 추가 SEC 심사 없이 증권� 등록하고 발행� � 있어 자본 조달 활동� 간소화됩니다. 공지에는 재무 조건, 거래 세부 사항 또는 수익 정보가 공개되지 않았습니�.

Jaguar Health, Inc. (NASDAQ : JAGX) a reçu un avis de la SEC indiquant que sa déclaration d'enregistrement en étagère Formulaire S-3 (Dossier n° 333-288202) est devenue effective le 27 juin 2025 à 16h00 ET. Cette prise d'effet permet à la société d'enregistrer et potentiellement d'émettre des titres à l'avenir sans examen supplémentaire de la SEC, simplifiant ainsi les activités de levée de fonds. Aucun terme financier, détail de transaction ou information sur les bénéfices n'a été divulgué dans l'avis.

Jaguar Health, Inc. (NASDAQ: JAGX) erhielt von der SEC die Mitteilung, dass seine Form S-3 Shelf-Registrierungserklärung (Aktenzeichen 333-288202) am 27. Juni 2025 um 16:00 Uhr ET wirksam wurde. Diese Wirksamkeit ermöglicht es dem Unternehmen, Wertpapiere künftig ohne zusätzliche SEC-Prüfung zu registrieren und auszugeben, was die Kapitalbeschaffung vereinfacht. Im Hinweis wurden keine finanziellen Bedingungen, Transaktionsdetails oder Gewinninformationen offengelegt.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine shelf S-3 effectiveness; neutral near-term impact.

The SEC EFFECT filing confirms Jaguar Health’s universal shelf registration is now active, giving management flexibility to issue equity, debt, or other securities when market conditions permit. While this can facilitate quicker fundraising, no immediate offering is announced, leaving dilution or leverage implications uncertain. Given the absence of deal size, pricing, or strategic context, the filing is largely administrative and does not materially alter the investment thesis at this stage.

Jaguar Health, Inc. (NASDAQ: JAGX) ha ricevuto comunicazione dalla SEC che la sua dichiarazione di registrazione a scaffale Form S-3 (File n. 333-288202) è diventata efficace il 27 giugno 2025 alle 16:00 ET. Tale efficacia consente all'azienda di registrare e potenzialmente emettere titoli in futuro senza ulteriori revisioni da parte della SEC, semplificando le attività di raccolta di capitale. Nel comunicato non sono stati divulgati termini finanziari, dettagli sulle transazioni o informazioni sugli utili.

Jaguar Health, Inc. (NASDAQ: JAGX) recibió aviso de la SEC de que su declaración de registro en estantería Formulario S-3 (Archivo No. 333-288202) se volvió efectiva el 27 de junio de 2025 a las 4:00 p.m. ET. Esta efectividad permite a la empresa registrar y potencialmente emitir valores en el futuro sin revisión adicional de la SEC, agilizando las actividades de recaudación de capital. No se divulgaron términos financieros, detalles de la transacción ni información sobre ganancias en el aviso.

Jaguar Health, Inc. (NASDAQ: JAGX)� SEC로부� Form S-3 선반 등록 명세�(파일 번호 333-288202)가 2025� 6� 27� 오후 4�(동부 시간 기준)� 효력� 발생했다� 통지� 받았습니�. � 효력 발생으로 회사� 향후 추가 SEC 심사 없이 증권� 등록하고 발행� � 있어 자본 조달 활동� 간소화됩니다. 공지에는 재무 조건, 거래 세부 사항 또는 수익 정보가 공개되지 않았습니�.

Jaguar Health, Inc. (NASDAQ : JAGX) a reçu un avis de la SEC indiquant que sa déclaration d'enregistrement en étagère Formulaire S-3 (Dossier n° 333-288202) est devenue effective le 27 juin 2025 à 16h00 ET. Cette prise d'effet permet à la société d'enregistrer et potentiellement d'émettre des titres à l'avenir sans examen supplémentaire de la SEC, simplifiant ainsi les activités de levée de fonds. Aucun terme financier, détail de transaction ou information sur les bénéfices n'a été divulgué dans l'avis.

Jaguar Health, Inc. (NASDAQ: JAGX) erhielt von der SEC die Mitteilung, dass seine Form S-3 Shelf-Registrierungserklärung (Aktenzeichen 333-288202) am 27. Juni 2025 um 16:00 Uhr ET wirksam wurde. Diese Wirksamkeit ermöglicht es dem Unternehmen, Wertpapiere künftig ohne zusätzliche SEC-Prüfung zu registrieren und auszugeben, was die Kapitalbeschaffung vereinfacht. Im Hinweis wurden keine finanziellen Bedingungen, Transaktionsdetails oder Gewinninformationen offengelegt.



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of June 2025
 
Commission File Number: 001-13742
 
ICL GROUP LTD.
(Exact name of registrant as specified in its charter)
 
ICL Group Ltd.
Millennium Tower
23 Aranha Street
P.O. Box 20245
Tel Aviv, 61202 Israel
(972-3) 684-4400
(Address of principal executive office)
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
 
Form 20-F ☒               Form 40-F ☐
 

ICL GROUP LTD.
 
CONTENTS

ICL Announces the Release of its Annual Corporate Responsibility (ESG) Report for 2024
 
The Company is pleased to announce the release of its Annual Corporate Responsibility (ESG) report for 2024 (the ”2024 Report") which is now accessible at the following link:  https://www.icl-group.com/wp-content/uploads/2025/06/ICL-2024-ESG-FINAL.pdf   The 2024 Report contained on our website is not part of or incorporated by reference into this Form 6-K.   The 2024 Report provides the Company's diverse stakeholders with easy access to their subjects of interest and covers a wide range of ESG topics.   The 2024 Report addresses the United Nations Sustainable Development Goals (SDGs), and includes Sustainable Accounting Standard Board (SASB) indicators, reference to the Global Reporting Initiative (GRI) standards, and the Task Force on Climate related Financial Disclosers (TCFD) indicators, in addition to the disclosures and information regarding climate-change risks and opportunities according to the core principles of the TCFD framework, within ICL’s 2024 Annual Report on form 20F, which was filed with the U.S. Securities and Exchange Commission on March 13, 2025 (Reference Number: 2025-02-016733).   The information in this Report of Foreign Private Issuer on Form 6-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.  

SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
ICL Group Ltd.
 
 
 
By:
/s/ Aviram Lahav
 
 
Name:
Aviram Lahav
 
 
Title:
Chief Financial Officer
 
 
ICL Group Ltd.
 
 
 
By:
/s/ Aya Landman
 
 
Name:
Aya Landman
 
 
Title:
VP, Chief Compliance Officer & Corporate Secretary
 
Date: June 30, 2025
 

FAQ

What did Jaguar Health (JAGX) announce in its EFFECT filing?

The SEC declared Jaguar Health’s Form S-3 shelf registration effective on June 27, 2025 at 4:00 p.m. ET.

Does the EFFECT filing mean Jaguar Health is issuing shares immediately?

No. The notice only confirms the shelf is active; no specific securities offering was announced.

Why is a Form S-3 effectiveness important for JAGX investors?

It streamlines future capital raises, allowing Jaguar Health to issue securities quickly when needed.

Were any financial terms or amounts disclosed in the EFFECT filing?

No financial amounts, pricing details, or transaction sizes were provided in the notice.

Could the shelf registration lead to dilution for existing JAGX shareholders?

Potentially, yes—if equity is issued under the shelf, shareholder dilution may occur, though no issuance is currently planned.
Icl Group Ltd.

NYSE:ICL

ICL Rankings

ICL Latest News

ICL Latest SEC Filings

ICL Stock Data

9.03B
722.29M
44.04%
23.06%
0.24%
Agricultural Inputs
Basic Materials
Israel
Tel Aviv